Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.30 - $15.50
Previous CloseN/A
Volume49.40K
Average Volume (3M)823.55K
Market Cap
$580.68M
Enterprise Value$199.39M
Total Cash (Recent Filing)$253.20M
Total Debt (Recent Filing)$5.78M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Jul 03, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding49,715,637
10 Day Avg. Volume1,446,552
30 Day Avg. Volume823,551
Financial Highlights & Ratios
PEG Ratio1.70
Price to Book (P/B)3.59
Price to Sales (P/S)0.00
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue41.33
Enterprise Value/Gross Profit261.32
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$28.00Price Target Upside143.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
KalVista Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySebetralstat showed significantly faster symptom relief and reduced attack severity in clinical trials, positioning it as a promising first oral therapy for hereditary angioedema.
Product LaunchKalVista Pharmaceuticals is well-prepared for a US launch of sebetralstat, demonstrating strong commercial readiness and engagement with prescribers, payors, and the patient community.
Regulatory ApprovalThe delay in FDA's decision is perceived positively as it suggests a likely approval for sebetralstat, with no additional concerns raised on safety, efficacy, or approvability.
Bears Say
FDA Resource ConstraintsThe delay due to FDA's resource constraints is worrisome for other ongoing reviews and upcoming PDUFA dates, potentially affecting the broader regulatory process.
Regulatory ConcernsReports of a push from FDA leadership to issue a CRL for sebetralstat without specific reasons could raise ongoing investor concerns about the regulatory landscape.
Ownership Overview
11.79% Insiders
15.56% Mutual Funds
0.22% Other Institutional Investors
63.06% Public Companies and Individual Investors
KALV FAQ
What was KalVista Pharmaceuticals’s price range in the past 12 months?
KalVista Pharmaceuticals lowest stock price was $7.30 and its highest was $15.50 in the past 12 months.
What is KalVista Pharmaceuticals’s market cap?
KalVista Pharmaceuticals’s market cap is $580.68M.
When is KalVista Pharmaceuticals’s upcoming earnings report date?
KalVista Pharmaceuticals’s upcoming earnings report date is Jul 03, 2025 which is in 5 days.
How were KalVista Pharmaceuticals’s earnings last quarter?
KalVista Pharmaceuticals released its earnings results on Mar 12, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of -$0.866 by -$0.054.
Is KalVista Pharmaceuticals overvalued?
According to Wall Street analysts KalVista Pharmaceuticals’s price is currently Undervalued.
Does KalVista Pharmaceuticals pay dividends?
KalVista Pharmaceuticals does not currently pay dividends.
What is KalVista Pharmaceuticals’s EPS estimate?
KalVista Pharmaceuticals’s EPS estimate is -0.84.
How many shares outstanding does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals has 49,715,637 shares outstanding.
What happened to KalVista Pharmaceuticals’s price movement after its last earnings report?
KalVista Pharmaceuticals reported an EPS of -$0.92 in its last earnings report, missing expectations of -$0.866. Following the earnings report the stock price went up 0.161%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals?
Currently, no hedge funds are holding shares in KALV
KalVista Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (143.48% Upside)
$28.00 (143.48% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 307.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $235.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 11.4%
Last 30 Days ▲ 20.5%
Last 30 Days ▲ 20.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.12%
12-Months-Change
Fundamentals
Return on Equity
-150.50%
Trailing 12-Months
Asset Growth
142.17%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
KALV Stock 12 Month Forecast
Average Price Target
$28.00
▲(143.48%Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Dianthus Therapeutics
―
Replimune Group
―
LENZ Therapeutics
―
GH Research
―